Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism (MOTHYRE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03951532|
Recruitment Status : Not yet recruiting
First Posted : May 15, 2019
Last Update Posted : September 18, 2019
"Early paediatric Basedow disease is one of the rare endocrine diseases for which the Reference Centre for Rare Endocrine Growth Diseases, was approved by the Ministry of Health in 2005. In addition, the study will benefit from the expertise of public Health France (SFP). This study is therefore part of the missions of these partners (reference centre for endocrine growth diseases and Public Health France).
For several years, our group has been interested in defining the evolutionary profile of these patients. A national study on short- and long-term patient follow-up has already been conducted, which has been the subject of two international publications29,30, as well as a study on a specific clinical form of the disease 24. This work was made possible thanks to the collaboration of paediatric clinical centres within the Reference Centre and Competence Centre for Rare Endocrine Diseases Network. The present study planned in France will make it possible to accurately characterize the care pathway and the frequency of complications associated with it at the national level.
|Condition or disease|
"With regard to the analysis of data on the identification of hyperthyroidism in children using the various medico-administrative databases, the epidemiological study of hyperthyroidism in children in France seems feasible using data on drug consumption from the SNIIRAM. These data will make it possible for the first time to study the impact of the disease in terms of serious morbidity and mortality (related to the disease and/or treatment) and to make recommendations for the management of the disease in order to improve the prognosis of the disease in children.
Thanks to these results, incidence data on the disease in children will be able to be estimated for the first time in France, as well as its temporal and spatial trends. They will be compared with national studies carried out in Sweden, Denmark and the United Kingdom on children. The spatial distribution in France can also be studied and compared with existing or emerging hypotheses, in particular concerning endocrine disrupters (French public health data). These analyses could also allow the generation of new causal hypotheses.
Finally, this work could lead to the establishment of national surveillance of hyperthyroidism in children. Prolonged follow-up is necessary, even after the end of medical treatment or after radical treatment, to determine the effectiveness of the management of patients during childhood and the impact on their overall health.
This study should therefore make it possible to propose recommendations to optimize the therapeutic management of hyperthyroidism in children and adolescents and improve the quality of life in adulthood for these patients.
The main objective of the study is to describe the complications (morbidity and mortality) associated with the 3 management modalities (treatment with synthetic antithyroid drugs (ATS), radioactive iodine and thyroidectomy) of children followed for hyperthyroidism in France, over a period of 11 years.
The study design chosen is that of an observational historical cohort study based on medico-administrative data from the National Inter-Regime Health Insurance Information System (SNIIRAM), which contains data from the PMSI (Information Systems Medicalization Program).
The study period begins on 01.01.2006 and ends on 31.12.2017.
|Study Type :||Observational|
|Estimated Enrollment :||1650 participants|
|Official Title:||Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism|
|Estimated Study Start Date :||September 2019|
|Estimated Primary Completion Date :||April 2020|
|Estimated Study Completion Date :||April 2020|
children with hyperthyroidism
children and adolescents (6 months -17 years included) whose data are present in the SNIIRAM database (DCIR data) and beneficiaries of the general health insurance scheme during the study period (01/01/2006-31/12/2017)
- number of complications morbidity [ Time Frame: for 11 years ]number of complications morbidity associated with the three management modalities (treatment with synthetic antithyroid drugs (ATS), radioactive iodine and thyroidectomy) of children followed for Maladie de Basedow in France, over a period of 11 years.
- number of complications mortality [ Time Frame: for 11 years ]number of complications morbidity associated with the three management modalities (treatment with synthetic antithyroid drugs (ATS), radioactive iodine and thyroidectomy) of children followed for Maladie de Basedow in France, over a period of 11 years.
- number of children and adolescents with a prescription or therapeutic modalities [ Time Frame: for 11 years ]description of the therapeutic modalities of children and adolescents with Basedow's disease according to geographical distribution and time in France over a period of 11 years.
- number of children with hyperthyroidism by geographical region and time in France [ Time Frame: for 11 years ]Estimation of the prevalence and incidence of hyperthyroidism in children by geographical region and time in France over a period of 11 years
- number of hyperthyroidism associated with other comorbidities [ Time Frame: for 11 years ]Estimate of the number of hyperthyroidism associated with other co-morbidities, in particular cardiovascular disease, psychiatric disorders and cancer, in children according to geographical region and time in France over a period of 11 years.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03951532
|Contact: Leger Juliane, PHDfirstname.lastname@example.org|
|Hôpital Robert Debré||Not yet recruiting|
|Paris, France, 75019|
|Contact: Leger Juliane, PHD 0140032354 email@example.com|
|Principal Investigator: Guilmin-Crepon Sophie|
|Principal Investigator: Kaguelidou Florentia|